secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0000950170-23-071084
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports positive initial Phase 2 data for paltusotine in carcinoid syndrome; 65% symptom reduction
--------------------------------------------------------------------------------

- 65% reduction in excess bowel movements and 65% reduction in flushing frequency in evaluable patients.
- No treatment-related severe or serious adverse events; most AEs mild-to-moderate (diarrhea, headache, abdominal pain).
- 87% (13/15) of completers enrolled in long-term extension; study enrollment complete (N=36).
- Topline results from full Phase 2 study expected in first half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023071084/0000950170-23-071084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023071084/crnx-20231218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-071084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer